{
  "pmcid": "8142440",
  "sha256": "074998931e9c2ffa3f778d04822a3967237a983368a4f8b51a910d64e98a660a",
  "timestamp_utc": "2025-11-09T22:57:30.744799+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.406479915433405,
    "reading_ease": 45.02917019027487,
    "word_count": 215
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of the CASPER Stent in Carotid Artery Stenting"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Randomisation and blinding details were not applicable as this was a single-arm study."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible patients had ≥50% symptomatic or ≥80% asymptomatic stenosis."
      },
      "Intervention": {
        "score": 2,
        "evidence": "A total of 140 patients underwent carotid artery stenting with the CASPER stent."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate its safety and effectiveness in patients at high or normal risk for carotid endarterectomy (CEA)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was the absence of major adverse events (MAEs) within 30 days and ipsilateral stroke within 1 year."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and blinding details were not applicable as this was a single-arm study."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Randomisation and blinding details were not applicable as this was a single-arm study."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 140 patients underwent carotid artery stenting with the CASPER stent."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The non-MAE rate was 98.6% (95% CI 94.4% to 99.6%), surpassing the performance goal."
      },
      "Harms": {
        "score": 1,
        "evidence": "The MAE rate was 1.4%, with two strokes reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: TCD-15152, UMIN000023562."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}